Activating mutations in KRAS occur in 32% of lung adenocarcinomas (LUAD). Despite
leading to aggressive disease and resistance to therapy in preclinical studies, the KRAS …

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class
of drugs for an old target—a narrative review - PMC Back to Top Skip to main content NIH NLM …

Non-small cell lung cancer (NSCLC) is the most frequent form of lung cancer and represents
a set of histological entities that have an ominous long-term prognosis, for example …

LKB1 (liver kinase B1) is a master regulator of several processes such as metabolism,
proliferation, cell polarity and immunity. About one third of non-small cell lung cancers …

The Kirsten rat sarcoma viral oncogene homolog (KRAS) and serine/threonine kinase 11
(STK11) co-mutations are associated with the diverse phenotypic and heterogeneous …

Aim This study aimed to evaluate the impact of KRAS status on the efficacy of first-line
immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer …

Kirsten rat sarcoma viral oncogene (K-ras) is a well-documented, frequently mutated gene in
lung cancer. Since K-ras regulates numerous signaling pathways related to cell survival and …

Background Chemoresistance is a major obstacle for the effective treatment of lung
adenocarcinoma (LAD). Forkhead box (FOX) proteins have been demonstrated to play …

Mutations of RAS oncogenes are responsible for about 30% of all human cancer types,
including pancreatic, lung, and colorectal cancers. While KRAS1 is a pseudogene, mutation …

The onset of non-small cell lung carcinoma (NSCLC) still be in the fog. LUCAT1 is
potentially capable of modulating MCL-1-involved NSCLC pathogenesis via targeting …